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Human Mycoplasma pneumoniae (MP) pneumonia is characterized by alveolar inﬁltration with
neutrophils and lymphocytes and lymphocyte/plasma cell inﬁltrates in the peri-bronchovascular area
(PBVA). No mouse model has been able to mimic the pathological features seen in human
MP pneumonia, such as plasma cell-rich lymphocytic inﬁltration in PBVA. To ﬁgure out the mechanism
for inﬂammation by MP infection using a novel mouse model that mimics human MP pneumonia, mice
were pre-immunized intraperitoneally with Th2 stimulating adjuvant, alum, alone or MP extracts with
an alum, followed by intratracheal challenge with MP extracts. The toll-like receptor-2, which is the
major receptor for mycoplasma cell wall lipoproteins, was strongly up-regulated in alveolar macro-
phages in a latter group after the pre-immunization but prior to the intratracheal challenge. Those
ﬁndings demonstrated that acceleration of innate immunity by antecedent antigenic stimulation can be
an important positive-feedback mechanism in lung inﬂammation during MP pneumonia.
& 2011 Elsevier B.V. Open access under CC BY-NC-ND license. 1. Introduction
Mycoplasma pneumoniae (MP) is a common pathogen in com-
munity acquired pneumonia. MP pneumonia can lead to acute
respiratory distress syndrome [1], and is sometimes fatal. MP is
an extracellular pathogen that adheres to mucosal surfaces of the
respiratory and genital tracts. Mycoplasmas lack cell walls, and
the cell membrane of an invading bacterium fuses with the hosteumonia, Mycoplasma
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Y-NC-ND license. cell membrane to induce an immune response [2,3]. Airway
diseases caused by MP include bronchiolitis, bronchitis, bronch-
iolitis obliterans and rarely, bronchiectasis. Recently, MP has been
implicated in the pathogenesis of asthma [4]. Epithelial cells play
an important role in recruiting inﬂammatory cells into the air-
ways [5]. While the clinical signiﬁcance of MP infection is evident,
the pathogenic mechanisms for lung inﬂammation have not been
well deﬁned.
Cumulative information on the pathogenesis of human MP
pneumonia has been gathered from pathological examination of
autopsy specimens [6–12]. There have also been limited albeit
important pathological reports based on studies of open lung biopsy
specimens [13–17], video-assisted thoracic surgery (VATS) [18],
and transbronchial lung biopsy (TBLB) [19–21]. According to these
reports, the most characteristic pathological feature of human MP
pneumonia is a marked plasma cell-rich lymphocytic inﬁltration in
the peri-bronchovascular area (PBVA) [12,13,16]. Lymphocytic alveo-
litis has also been reported in these studies. In murine models,
intranasal inoculation with alive MP has been shown to cause initial
neutrophilic inﬁltration of the alveoli, followed by lymphocytic
Table 1
Experimental schedule.
Events Timing Treatments
T. Saraya et al. / Results in Immunology 1 (2011) 76–87 77inﬁltrates thereafter. In contrast to human pathology, no murine or
other animal models have exhibited prolonged plasma cell inﬁltration
of the PBVA.
An excessive and inappropriate immune response against MP
seems to be the major contributing factor in the pathogenesis of MP
infection. Extrapulmonary manifestations, including arthralgia,
Guillain-Barre´ syndrome, myocarditis, pericarditis, acute myocardial
infarction, hemolytic anemia, disturbances to the coagulation
mechanism, and Stevens-Johnson syndrome have been reported as
complications of MP pneumonia [22]. A study has shown that
peripheral blood lymphocytes respond more strongly to MP extracts
among recently infected patients compared to healthy controls [23].
In addition, delayed type hypersensitivity reactions to heat-killed
MP extracts are observed in skin tests of patients with MP
pneumonia [24], while anergy to the tuberculin skin test has been
well recognized in the early phase [25]. Alternatively, MP extracts
may induce lung inﬂammation through up-regulation of host innate
immunity. Recent studies in both mice [26] and humans [27]
revealed that MP causes persistent but latent infection in the lower
respiratory tracts, which may up-regulate host innate immunity.
Innate immunity against invading microbes is initiated by
pathogen recognition by toll-like receptors (TLRs) followed by
activation of host inﬂammatory responses. Among the 12 TLR
family members, TLR-2, TLR-4, TLR-5 and TLR-9 have been
implicated in the recognition of different bacterial components.
Peptidoglycan, lipoarabinomannan, zymosan, and lipoproteins
from various micro-organisms are recognized by TLR-2 [28],
while lipopolysaccharide, bacterial ﬂagellin, and bacterial DNA
are recognized by TLR-4, TLR-5 and TLR-9, respectively. These TLR
family members are known to activate nuclear factor kB (NF-kB)
via sustained phosphorylation of p38 mitogen-activated protein
kinase (MAPK). In MP pneumonia, it has been reported that TLR-2
signaling is involved in inﬂammatory cell activation by myco-
plasma-derived lipoproteins [29]. Chu et al. demonstrated that
expression of TLR-2 mRNA and protein on alveolar macrophages
(AMs), and the recruitment of adaptor protein MyD88 increases
after MP infection [30]. In this regard, Hayakawa et al. [31], Sekine
et al. [32], and Chu et al. [33] in turn demonstrated that pre-
immunization with alive MP or its extract signiﬁcantly augmen-
ted the inﬂammatory responses after the second challenge. Thus,
it is likely that subclinical, latent infection of MP in the lower
respiratory tracts may up-regulate TLR-2 expression on AMs and
bronchial epithelial cells augmenting MP reactivity.
In this study mice were immunized with MP extracts to mimic
human MP pneumonia, and thereafter challenged with the same
extracts by intratracheal exposure. We found that stimulation by
MP extracts up-regulated baseline expression of TLR-2 on AMs
and augmented their response to the subsequent challenge by
the same extracts. Our results demonstrated that preceding or
latent respiratory MP infection may trigger and synergistically
augment inﬂammatory processes against MP extracts through
up-regulation of host innate immunity.Pre-immunization
(intraperitoneal)
6 and 13 days prior to
intratracheal challenge
Pre-immunization with
alum alone or with alum
plus MP extracts
Intratracheal
challenge
Day 0 Intratracheal challenge
with MP extracts
BAL analysis 0, 8, 24, 48, 96, 168, and
336 h after intratracheal
challenge
Sampling for lung
pathology
0, 8, 24, 48, 96, 168, and
336 h after intratracheal
challenge
alum: a Th2 stimulating adjuvant, MP extract: Mycoplasma pneumoniae extract,
derived from centrifugation of sonicated particle of alive Mycoplasma pneumoniae,
described in the ‘‘Preparation of MP extracts’’ section above mentioned in the
‘‘Material and methods’’ section.2. Material and methods
2.1. Preparation of MP extracts
MP, ATCC29342 strain (American Type Culture Collection,
Rockville, MD) was cultured in PPLO broth (Nikken Bio Medical
Laboratory, Tokyo) at 37 1C under 5% CO2 for 6 day. MP was
collected by centrifugation at 10,000g for 25 min, washed three
times with Hanks’ balanced salt solution (HBSS, Gibco, NY), and
resuspended in distilled water. After undergoing homogenization
10 times for 60 s using a sonicator (Soniﬁle 250, Branson Ultra-
sonics Co, CT), the suspension was centrifuged at 10,000g for5 min and, the supernatant was ﬁltered, to derive ‘‘MP extracts’’.
The protein concentration was determined by Bio-Rad Protein
Assay (Bio-Rad Laboratories, Tokyo), adjusted to 1 mg/mL with
distilled water, and the aliquots were stored at 80 1C until use.
Lipopolysaccharide contamination was 0.1 I.U./mL by limulus
test, which showed no effect on stimulation of murine alveolar
macrophages [34].
2.2. Animals and inoculation
Female BALB/c (7 week old) mice were purchased from Nippon
Charles River (Tokyo), and fed with CE-2 (CLEA Japan, Inc.) in a
speciﬁc pathogen free (SPF) environment. All mice were inocu-
lated intratracheally with MP extracts with or without pre-
immunization. Pre-immunization was carried out by intraperito-
neal injection at 6 and 13 day prior to the intratracheal challenge
(IT). Treatment models included; Model A: IT without pre-
immunization; Model B: IT after twice pre-immunizing with MP
extracts alone; Model C: IT after twice pre-immunizing with MP
extracts plus CpG; Model D: IT after twice pre-immunizing with
alum alone; and Model E: IT after twice pre-immunizing with MP
extracts plus alum. As shown in Table 1, One week following the
last immunization, mice were intraperitoneally anesthetized with
40 mg/kg of pentobarbiturate (Nembutal, Dainippon Sumitomo
Pharma Co., Tokyo) and 80 mg/kg of medetomidine hydrochloride
(Domitors, Orion corporation, Finland), and underwent IT with
50 mg of MP extracts. Bronchoalveolar lavage ﬂuid (BALF) and
lung specimens were obtained before this process and 8, 24, 48,
96, 168 h after IT. These procedures were approved by the
Institutional Experimental Animal Ethics Committee of Kyorin
University.
2.3. Titration of the serum antibody speciﬁc for MP
Serum antibody titers against MP were determined before
and after pre-immunization by particle-agglutination test, using
Serodia MycoII (Fujirebio, Tokyo).
2.4. Histopathology
After mice were euthanized, 10% formalin solution (2 mL) was
instilled into the bronchial tree, and the lungs were ﬁxed for
14 day. Parafﬁn embedded sections were then prepared, deparafﬁ-
nized, and stained with hematoxylin–eosin (HE) or other immuno-
histochemical staining. Stained lung sections were evaluated for the
degree of inﬂammation by counting cells inﬁltrate within the
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All inﬂammatory cells were counted at 200 magniﬁcation. The
number of neutrophils, lymphocytes, and macrophages were enum-
erated by three independent pathologists based on the cell morphol-
ogy. Neutrophil inﬁltration within alveoli was deﬁned as none (),
mild (þ , up to 150 cells/ ﬁeld), moderate (þþ , from 150 to 500
cells/ﬁeld), or severe (þþþ , greater than 500 cells/ﬁeld). Similarly,
the degree of lymphocytic inﬁltration within alveoli was deﬁned as
none (), mild (þ , up to 5 cells/ﬁeld), moderate (þþ , from 5 to
15 cells/ﬁeld), or severe (þþþ , greater than 15 cells/ﬁeld). Peri-
bronchovascular inﬁltration by lymphocytes was deﬁned as none
(), mild (þ , up to 150 cells/ﬁeld), moderate (þþ , from 150 to
350 cell counts/ﬁeld), or severe (þþþ , greater than 350 cells/ﬁeld),
while peri-bronchovascular inﬁltration by plasma cells was deﬁned
as none (), mild (þ , up to 10 cells/ﬁeld), moderate (þþ , from 10
to 50 cells/ﬁeld), or severe (þþþ , greater than 50 cells/ﬁeld).
2.5. Immunohistochemistry
CD3þ T cells and plasma cells were detected by immunohis-
tochemically using anti-CD3 antibody (Dako, CA, USA) and anti-
CD138 antibody (Dako, CA, USA), respectively. For the negative
control, we used murine IgG.
The expression of RANTES, MCP-1, and TLR-2 were also analyzed
immunohistochemically using polyclonal rabbit antibodies against
TLR-2 (TLR-2 antibody—Aminoterminal end, ab47840), RANTES
(R&D Systems, MN, USA), and MCP-1 (Hycult biotech Inc, Eindhoven
area, Netherlands), respectively. For the negative controls, we used
rabbit IgG (Dako, CA, USA). Color development was performed using
3-amino-9-ethyl carbazole (Dako, Glostrup, Denmark) or diamino-
benzidine (Nichirei, Tokyo). The number of TLR-2/cytokine/chemo-
kine positive lung cells were counted in each lung ﬁeld (200 ) by
microscopy, with counts reaching up to 250/ﬁeld with a total of ﬁve
ﬁelds/mouse.
2.6. Cellular response to MP extracts
Spleens were minced in RPMI 1640 with 5% fetal bovine serum
(FBS), and the resulting cell suspension was passed through a
nylon mesh, and centrifuged at 2000g for 5 min. The cells were
washed twice with phosphate-buffered saline without calcium/
magnesium chloride (PBS-) and were resuspended in RPMI 1640
with 5% FBS (Iwaki, Tokyo) at a density of 106 cells/mL. Two
hundred microliters of the suspension was added to each well
in a ﬂat-bottomed microtiter plates (Iwaki, Tokyo). In the
same manner, bronchoalveolar lavage ﬂuid (BALF) cells were
harvested. Thereafter, 10 mg of MP extracts was added to each
well followed by incubation at 37 1C for 72 h under 5% CO2.
The cells were pulsed with [methyl-3H] thymidine (Moravek
Biochemicals, Inc. CA) for 16 h, and uptake was measured using
a liquid scintillation counter. In some experiments, AMs were
puriﬁed from BALF by plastic adhesion for 30 min at 37 1C
under 5% CO2, collected by gentle scraping using a cell scraper
(Falcon, Ann Arbor, MI), resuspended in RPMI 1640 with
5% FBS (Iwaki), added to a 24 well plate (Falcon) at 2104
cells/well, and incubated in the presence or absence of MP
extracts (10 mg/mL). After 8 h, culture supernatants were stored
at 80 1C further use.
2.7. Bronchoalveolar lavage (BAL)
BAL ﬂuid was obtained after sacriﬁce through 1-cm long-
itudinal incision that was made to expose the trachea. BALF was
obtained before and, 8 and 24 h after IT inoculation by instilling
1 mL of HBSS through a 25-gage needle inserted into the tracheal
rings. A retrieved aliquot was centrifuged at 1500g for 5 min, andthe supernatant was stored at 80 1C for analysis of cytokines
levels in BALF. In some cases, the cell pellet was resuspended
in HBSS, the density was counted by a hemocytometer, and
the differentials were determined by counting 300 cells on a
cyto-centrifuge slide after staining with Diff Quick (Kokusai
Shiyaku Co. Ltd., Kobe).
2.8. Determination of cytokine/chemokine level
Concentrations of TNF-a, IL-1b, IL-6, MIP-2, MIP-1a, KC,
MCP-1, and RANTES in BALF or culture supernatants were
measured using MILLIPLEXs (# MPXMCYTO, Millipore, MA)
according to manufacturer’s instructions.
2.9. Real-time quantitative PCR (RT-qPCR)
Expression of TLR-2 mRNA in AMs was evaluated by real-time
quantitative PCR. Because BALF cells consisted of mostly AMs in
both model E (mean7SD; 96.172.5%) and model D (9574%),
respectively, we used total BALF cells without any puriﬁcation
procedure. Total RNA was extracted from alveolar macrophages
using TRIzols (Invitrgen Life Tech, CA, USA) and the RNeasys mini
kit (QIAGEN, Frankfurt, Germany), incubated with DNase I followed
by reverse transcription using the SuperScripts ﬁrst strand synthesis
system for RT-PCR (Invitrogen). The reaction mixture included
154 ng of total RNA and random hexamers (50 ng). The mouse
TLR-2 primers and probes for RT-qPCR have been previously
reported [35]. TLR-2 (GenBank accession number, AF124741) pri-
mers and probes: forward primer, 5_-AAGGCATTAAGTCTCCGGAAT-
TATC-3_; reverse primer, 5_-TCGCTTAAGTGAAGAGTCAGGTGAT-3_;
probe, 5_-TCCCAAAGTCTAAAGTCGATCCGCGAC-3_. The qPCR was
performed using the PCR Thermal Cycler Dice Real Time System
TP800 (TaKaRa, Japan, Kyoto). The sample mixture contained 60 ng
of cDNA, 100 nM of ﬂuorogenic probe, 200 nM of primers, and
Premix Ex Taq (TaKaRa). The reaction conditions included 30 s of
pre-incubation at 95 1C followed by 99 cycles for 5 s at 95 1C and
40 s at 60 1C. Appropriate non-template controls were included in
each PCR reaction. Relative expression levels of TLR-2 were calcu-
lated from relative levels of GAPDH (Applied Biosystems, Inc., CA).
2.10. Statistical analysis
Numerical data were evaluated for a normal distribution using
the Shapiro–Wilk test and for equal variance using the Levine
median test. Data were presented as the means7SD. Statistical
comparisons of data were made by Student’s t test. All tests were
2-sided, and p-values of less than 0.05 were considered to be
statistically signiﬁcant.3. Results
3.1. Comparison of histopathological features in mice models
To establish the most appropriate mouse model that would
mimic human MP pneumonia, we ﬁrst carried out a review of the
previous literature on the histopathology of human MP pneumo-
nia as shown in Table 2. The major pathological ﬁndings reported
in human MP pneumonia are neutrophilic and lymphocytic
inﬁltration in the alveolar spaces and lymphocytic and plasma-
cytic inﬂammation in the PBVA. Neutophils/lymphocyte alveolitis
has been variably reported among cases where specimens were
obtained at autopsy [6–12], or from open [13–17], and video
assisted [18], transbronchial biopsies [19–21]. Lymphocytic and
plasmacytic inﬁltration of the PBVA would therefore constitute
the most characteristic ﬁnding in human MP pneumonia.
Table 2
Summary of the literature cases regarding pathological features of MP pneumonia in human and animal models.
Category No. of reports/cases Alveolar PBVA Reference
Number of cases positive for inﬁltration with
Neu Lym Lym Plasma
Autopsy 7/16 9 3 9 11 [6–12]
Open lung biopsy and video-assisted thoracic surgery 6/13 3 0 11 9 [13–17,18]
Transbronchial lung biopsy 6/7 0 1 4 2 [19–21]
Murine model 11/11 6 3 10 0 [26,31,33,36–43]
Day 1–3 (n) 5 3 6
Day 4–7 (n) 1 1 3
Day 8– (n) 1 1 3
Hamster model 4 [44–47]
Guinia-pig model 1 [48]
Day 1–3 (n) 1
Day 4–7 (n) 2
Day 8– (n) 4
Neu: neutrophil, Lym: lymphocyte, Plasma: plasma cell, Alveolar: alveolar area, PBVA: peri-bronchovascular area.
(n): number of positive cases at various phases (early: day 1–3, middle: day 4–7, late stage: day 8–, in each report. If the one mouse model had
lymphocytes inﬁltration in the alveolar area from an early to middle stage, this was counted as early (n¼1) and middle stage (n¼1).
Table 3
Pathological ﬁndings of mouse lung inoculated with MP extracts.
Models Pre-immunization with Intratracheal challenge with Inﬁltration alveolar Inﬁltration PBVA Other ﬁndings
MP extracts Alum CpG Mp extracts Neua Lymb Lymc Plasmad
A    þ þ þ  
B þ   þ þþ þ þ / 
C þ  þ þ þþþ þþþ þþþ 
D  þ  þ þþ þþ þþ þ Alveolitis
Intraalveolar hemorrhage
E þ þ  þ þþþ þþþ þþþ þþþ Hyperemia in small arteries
Hyperplasia of type II alveolar
epithelial cells
Pre-immunization was intraperitoneally performed once a week for twice.
CpG: a Th-1 stimulating adjuvant, alum: a Th2 stimulating adjuvant, Neu: neutrophil, Lym: lymphocyte, Plasma: plasma cell, Alveolar: alveolar area, PBVA: peri-
bronchovascular area, MP extract: Mycoplasma pneumoniae extract.
All mice were inoculated by IT with MP extracts with or without pre-immunization. Pre-immunization was carried out intraperitoneally on 6 and 13 day prior to IT.
Models include; Model A: without pre-immunization. Model B: following two IP immunizations with MP extracts alone. Model C: following two IP immunizations with MP
extracts plus CpG. Model D: following two IP immunizations with aluminum adjuvant alone. Model E: following two IP immunizations with MP extracts plus aluminum
adjuvant.
a The degree of inﬁltration of neutrophils in the alveolar spaces was deﬁned as none (), mild (þ , up to 150 cells/ﬁled), moderate (þþ , from 150 to 500 cells/ﬁeld), or
severe (þþþ , greater than 500 cells/ﬁeld).
b The degree of inﬁltration of lymphocytes in the alveolar spaces was deﬁned as none (), mild (þ , up to 5 cells/ﬁeld), moderate (þþ , from 5 to 15 cells/ﬁeld), severe
(þþþ , greater than 15 cells/ﬁeld).
c Peribronchovascular inﬁltration of lymphocytes was deﬁned as none (), mild (þ , up to 150 cells/ﬁeld), moderate (þþ , from 150 to 350 cell counts/ﬁled), or severe
(þþþ , greater than 350 cells/ﬁeld).
d Peribronchovascular inﬁltration with plasma cells was deﬁned as none (), mild (þ , up to 10 cells/ﬁeld), moderate (þþ , from 10 to 50 cells/ﬁeld), severe (þþþ ,
greater than 50 cells/ﬁeld).
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murine models, perhaps reﬂecting the inadequacy of murine
models in mimicking human MP pneumonia precisely. In the
present study, we designed ﬁve different mouse models. As
shown in Table 3, models C and E were associated with neutrophil
and lymphocyte inﬁltration in the alveolar spaces and as well as
inﬂammation in the PBVA to the same extent. However, an
increase in plasma cells in the PBVA, was observed in only model
E and D. The subsequent analyses were therefore performed using
model E, with model D used as the control. As alum is known
to augment Th2 responses in host immunity, plasma cell inﬁltra-
tion in PBVA may be associated with not only pre-immunization
but also an acceleration in Th2 responses prior to IT with MP
extracts.3.2. Pulmonary alveolar inﬂammation after IT inoculation
To evaluate the effect of IP with MP extracts on acquired
immunity, we measured the serum antibody titer against MP 6
days after the ﬁnal IP inoculation. The mean titer was found to be
4177319 in mice immunized with MP extracts plus alum, whereas
it was not detected in mice with alum alone (detection limit was
40 ) (Fig. 1). This demonstrated the development of humoral
immunity against MP occurring after two IP immunizations with
MP extracts plus alum. We evaluated the histopathological features
at 6 days after the last IP immunization with and without MP
extracts. Neither neutrophil nor lymphocyte inﬁltration was
observed in the alveoli in both cases, whereas this was observed
in BALF samples from both mice (data not shown). Moreover, the
p<0.001
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histopathological changes were also compared sequentially between
models E and D at 0, 8, 24, 48, 96, and 168 h after IT. Although IT
initiated inﬂammation in both models E and D, it was more
predominant in model E compared to model D. There was marked
neutrophil inﬁltration but less impressive macrophage and lympho-
cyte involvement during the ﬁrst 24 h. In fact, neutrophil inﬁltration
was seen in the alveolar spaces as early as 8 h and peaked at 24 h in
both models E and D (Fig. 2A and C). Meanwhile, AMs were
decreased between 8–24 h. From 24–48 h, the number of neutro-
phils gradually became decreased in the alveolar spaces, while
lymphocyte numbers continued to increase (Fig. 2B and C), peaking
at 96 h in both models. Thereafter, a decrease in lymphocytes was
noted in both model D and E. These ﬁndings showed that IT induced
an early neutrophilic inﬁltrate within the alveolar spaces followed
by a later lymphocytic inﬁltrate.
3.3. Lymphocyte inﬁltration in the PBVA
At 48 h, mild to moderate lymphocyte inﬁltration was
observed in the PBVA in both models (Fig. 3A–D), although more
predominantly in model E. By 168 h, these inﬁltrates continued to
persist and increase in model E, but were less remarkable and
scant in model D.
3.4. Plasma cell inﬁltration in the PBVA
As shown in Fig. 4A–D, plasma cell inﬁltration, as detected by
immunohistochemistry using anti-CD138 antibodies, were
observed at 96 h in both the perivascular peribronchiolar areas
in model E and less impressively in model D. Thereafter, inﬁl-
trates were noted to decline and began to disappear in model D as
early as 168 h (Fig. 4A–D). Conversely, plasma cells increased
dramatically between 96 and 168 h in model E and persisted until
336 h (data not shown). These results suggest that pre-immuni-
zation with MP extracts up-regulates plasma cell recruitment
within the PBVA.
3.5. Sequential changes in BALF cells
To conﬁrm the aforementioned time kinetics of the inﬂamma-
tory responses induced by IT, BALF cells were sequentially
analyzed. Neutrophil counts demonstrated an increase as early
as 8 h, peaked at 24 h, and decreased to baseline levels by 96 h, as
consistent with histopathological ﬁndings. The number of neu-
trophils at 8 and 24 h were 4.0- and 4.7-folds greater in model E(9.9105 and 2.0107 cells/lung, respectively) than in model D
(2.5105 and 4.2106 cells/lung, respectively (Fig. 5A). An
increase in lymphocytes was observed as early as 24 h in only
model E, reaching the maximum at 48 h before gradually declin-
ing to levels that were still detectable at 336 h. In contrast, an
obvious increase in lymphocytes in model D was not observed
throughout the whole course (Fig. 5B). We conﬁrmed that these
increased lymphocytes were consisted of CD3þ/CD19 and
CD3-/CD19 cells using ﬂowcytometry (Supplementary Fig. 2).
These results suggested that pre-immunization with MP extracts
is a crucial process in the long-term lymphocyte alveolitis model.
3.6. Reactivity of BALF lymphocytes to MP extracts in vitro
To evaluate the effect of pre-immunization on the host cellular
immunity, we investigated the speciﬁc response of BALF cells to
MP extracts in vitro at 96 h after IT in models E and D. The
stimulation indices were 0.5 and 0.7 for model E and D, respec-
tively (Fig. 6A), which demonstrated a lack of response of BALF
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cytes did not recognize MP extracts. In contrast, the stimulation
index of splenic lymphocytes was 1.76 in model E and 0.95 in
model D (Fig. 6B). These data suggested that IP immunization of
MP extracts induced antigen-speciﬁc cellular immunity systemi-
cally, but not in the lung. Consequently, lymphocyte alveolitis
may not be caused by MP extracts speciﬁc proliferation.
3.7. Chemokine and cytokine increase in BALF after IT inoculation
Various chemokines are believed to be responsible in inducing
lymphocytic alveolitis, as well as initial neutrophilic inﬁltration. An
analysis of BALF after IT revealed that the expression of chemokines
and inﬂammatory cytokines was up-regulated in model E. Cytokine/
chemokines levels in models D and E were also analyzed at 8 and
24 h post-IT. KC, IL-6, TNF-a, and MIP-2 were all detected at 8 h in
both models, but only RANTES was signiﬁcantly higher in model E
than model D (data not shown). At 24 h, IL-6, MCP-1, MIP-2, and
RANTES were higher in model E than in model D, while IL-1b and KC
levels were similar in both (Fig. 7). As both MCP-1 and RANTES are
known to be a potent lymphocyte and neutrophil chemo-attractants, the increase was consistent with the histopathological
features observed during the 8–96 h period after IT.
3.8. AMs as a possible source for inﬂammatory cytokines/
chemokines
As AMs play a central roles in host innate immunity in the
lung, we evaluated the chemokine/cytokine production from AMs
after stimulation with MP extracts in vivo and in vitro. At 48 h
post-IT, MCP-1 and RANTES were strongly detected in AMs in
model E compared to model D. In contrast, MCP-1 and RANTES
were weakly stained in other lung cells such as bronchial
epithelial cells and alveolar type II cells, as these chemokines
were mainly produced in AMs (Fig. 8A). We also evaluated in vitro
AMs cytokine production in the presence or absence of MP
extracts. AMs were obtained from BALF at 6 day after two IP
immunizations with MP extracts plus alum or with alum alone.
When we compared the concentration of cytokines in the culture
supernatants, the production of IL-1b, IL-6, MIP-2, and RANTES
after 8 h incubation, was strikingly greater in the former than the
latter (Fig. 8B), indicating that pre-immunization with MP
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extracts. Taken together, it is likely that AMs primed with two
IP immunizations with MP extracts constituted the major effector
cells in facilitating the initial neutrophilic/lymphocytice inﬁltra-
tion after IT.
3.9. Up-regulation of TLR-2 expression on AMs
Previous studies have demonstrated that mycoplasma cell wall
antigens activate MAPK-NF-kB signaling in AMs through TLR-2.
Thus, we evaluated the expression of TLR-2 on AMs at 6 day after
two IP immunizations with MP extracts plus alum or alum alone.
The number of TLR-2 positive AMs in the alveolar spaces 4.6 times
greater in model E (86.9%) than in model D (18.5%) (Fig. 9A and B),
whereas the number of TLR-2 positive epithelial cells was even
between model D and E. The expression of mRNA in BALF cells
obtained from model E were 3.0 times higher than in model D
(Fig. 9C). To elucidate that TLR-2 signaling is involved in cytokine
production, we performed an inhibition assay using a MAPK
inhibitor, SP600125 for JNK (c-Jun N-terminal kinase) enzymes.
The inhibitor completely abrogated the production of IL-6 by AM
stimulated with MP extracts in vitro (Fig. 9D).4. Discussion
The aim of this study was to reproduce the inﬂammatory
processes seen in human MP pneumonia using a novel mouse MP
pneumonia model. None of the previously reported murine
models [26,31,33,36–43] or other animal models [44–48]
described persistent plasma cell inﬁltration in the PBVA. Thus,
this is the ﬁrst report that describes a murine model with
longstanding plasma cell inﬁltration in the PBVA.
This study also described the chronological sequence of
inﬂammatory events in MP pneumonia both quantitatively and
qualitatively. We conﬁrmed that neutrophil inﬁltration precedes
lymphocyte inﬁltration in both lung sections and BALF, which is
consistent with previous studies [33,36,40]. The peaked cell
density was 4-fold higher in model E than D, suggesting that
the effect of pre-immunization with MP extracts was a potent
promoter of neutrophil inﬁltration. Similarly, in model E, lym-
phocyte inﬁltration peaked at 48 h, lasting up to 336 h, an effect
that was not observed in model D. Our study differs from previous
murine models in that we chose to utilize intraperitoneal pre-
immunization with MP extracts plus alum prior to IT with MP
extracts to augment the reactivity of immune cells to the extracts.
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T. Saraya et al. / Results in Immunology 1 (2011) 76–87 83Surprisingly, IT with mycoplasma cell free extracts alone was
found to be sufﬁcient to induce marked inﬁltration of neutrophils
and lymphocytice alveolitis with prolonged lymphocyte/plasmacell inﬂammation in the PBVA. Moreover, the pathological obser-
vation revealed that recruitment of lymphocytes into alveolar
spaces after IT in protocol D resulted in peak lymphocyte
numbers equal to those seen in protocol E. The result suggests
that at least a major portion of the recruited cells are not antigen-
speciﬁc. This is supported by the very low stimulation index (o2)
reported in Fig. 6. Although previous studies have demonstrated
that inoculation of living MP induces inﬂammation in the lower
respiratory tract in mice [33,36,37], this study suggests that an
exaggerated host immune response to MP antigens may be
involved in the inﬂammation in human MP pneumonia. Serodia
MycoII is a kit which detect MP speciﬁc antibody, especially in
IgM antibody. The Adjuvant ‘‘alum’’ was known for Th2-inducing
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T. Saraya et al. / Results in Immunology 1 (2011) 76–8784adjuvant. Furthermore, we conﬁrmed that using Th-1 inducing
adjuvant ‘‘CpG’’ in our model C did not cause plasma cell
inﬁltration in the PBVA (Table 3). Those ﬁndings suggested that
Th2 reaction was essential to induce the plasma cell inﬁltration in
the lung, which implies the possible involvement of Th2
responses in the process of human MP pneumonia.
Another aim of this study was to determine the role of innate
immunity in MP pneumonia. We demonstrated that the ﬁrst
process is possibly up-regulation of TLR-2 expression on AMs
that subsequently induces cytokine/chemokine production in
response to subsequent challenges with the same MP extracts.
This concept is supported by the following data. Firstly, pre-
immunization with MP extracts up-regulated TLR-2 expression on
AMs. Secondly, AMs from mice immunized with MP extracts plus
alum produced higher amounts of RANTES and MCP-1 than mice
immunized with alum alone. Recent studies have focused on
innate immunity mediated by TLRs on macrophages or epithelial
cells. Among the 12 TLRs, TLR-2 signaling is the major pathway
for inﬂammation with MP pneumonia [30]. Studies have identi-
ﬁed three lipoproteins/lipopeptides extracted from MP as ligands
for TLR-2 [29]. These ligands up-regulate the expression of TLR-2,
activate the MAPK-NF-kB signaling pathway, and augment the
production of TNF-a, IL-6, and IL-1b. In TLR-2/ mice, alive MP
failed to stimulate MyD88 NF-kbp65 activation. Moreover, anti-
bodies to TLR-2 blocked an increase in IL-6 in BALF after
intranasal inoculation [30], and its production was completely
diminished in TLR-2 KO mice. It has further been demonstrated
that activation of the TLR-2 pathway is essential for inﬂammation
in response to MP [49]. The consistent increase in cytokine/
chemokine production from AMs in model E but not model D
was due to up-regulated expression of TLR-2 on AMs.Previous studies reported that MCP-1 was the most potent
activator of T lymphocytes [50], and that RANTES plays an
important role in effector CD8þ T cell transmigration from
alveolar capillaries into the pulmonary interstitium [51]. Many
cell types have been reported to produce RANTES including
activated T lymphocytes, bronchial cells, ﬁbroblasts, macro-
phages, and endothelial cells [52]. As shown in our study, AMs
from mice pre-immunized with MP extracts plus alum are likely
to be potent inducers of RANTES and MCP-1. Other factor such as
vascular endothelial growth factor (VEGF) from small airway
epithelial cells [53] and endothelial cells [54] might be a possible
explanation for long-lasting characteristics of MP pneumonia
through angiogenesis and microvascular remodeling.
It is still unknown why TLR-2 expression on AMs is up-
regulated after intraperitoneal immunization of MP extracts plus
alum. It is unlikely that circulating MP extracts directly stimulate
AMs or their precursors in the alveolar spaces. In this regard,
Fan et al. [55] reported that TLR-2 expression on AMs was up-
regulated through TLR-4 by shock-activated neutrophils in vivo
and in vitro. Neutrophil NADPH oxidase-derived oxidants signal-
ing mediates the TLR-2–TLR-4 cross talk both in endothelial cells
and in AMs, which results in the activation of positive feedback
signals against invading pathogens.5. Conclusion
The present study highlights distinct reaction to IT between
mice with and without pre-immunization of MP extracts. Our
results suggest that subclinical or preceding MP infection may
greatly inﬂuence the degree of inﬂammation in MP pneumonia.
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T. Saraya et al. / Results in Immunology 1 (2011) 76–87 85Unraveling the mechanisms by which innate immunity regulates
cytokine/chemokine expression will signiﬁcantly improve our
understanding of the pathogenesis of MP and will help to develop
novel therapeutic strategies to control mycoplasma associated
infections in humans.Competing interests
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